Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Re-Earning the Public Trust

This article was originally published in RPM Report

Executive Summary

Pharma has made big changes in marketing and promotion practices and the systems to assure compliance, but the industry’s ethical image is lagging the efforts at reform. Pfizer Specialty Care/Oncology President Geno Germano says a shared commitment among companies to convince the public of the impact of the industry’s compliance reforms is the key to a healthy environment for the industry.

You may also be interested in...



GSK Leads the Way to Needed Change in Sales Reps Compensation

Will other companies follow a model that can increase trust?

Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks

Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.

Public Interest/Private Sector: Perspectives on Conflict of Interest

Conflict of interest remains a thorny topic in the conduct, analysis and dissemination of clinical trials. Four panelists on a recent Windhover Webinar offer their perspectives on how private companies can best align with the public interest goals of medical research.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel